中文
At present,the Yangtze River Delta region is strengthening cross regional collaboration between scientific and technological innovation and industrial innovation,achieving strong alliances,and creating a source of scientific and technological innovation.Recently,during a symposium with major leaders in the Yangtze River Delta region,Jin Xia,Executive Vice Chairman and Secretary General of the Yangtze River Delta Data Driven Innovation Biomedical Industry Chain Alliance and Chairman of Huoshi Creation Technology Co.,Ltd.,stated in an interview with reporters that”close”is a major keyword.”Whether from the perspectives of policy,regulation,factors,or upstream and downstream collaboration in the industrial chain,the integration and cooperation in the Yangtze River Delta region have become increasingly close.”
“Taking the biopharmaceutical industry chain alliance as an example,whether it is a revolutionary breakthrough in biotechnology,innovative allocation of production factors,or upgrading of the industry chain,adding data as a new production factor to the biopharmaceutical industry chain will bring earth shaking changes to the industry.Now,the transformation brought by data is just beginning,and it is expected that the Yangtze River Delta can build an industrial data infrastructure,improve overall configuration efficiency through data intelligence,and further enhance the competitiveness of the biopharmaceutical industry in the Yangtze River Delta.”Jin Xia said.
At the 2024 Yangtze River Delta Entrepreneurs Alliance Summit during the conference,the”Yangtze River Delta Biomedical Industry Integration Index”was jointly released by the Yangtze River Delta Data Driven Innovation Biomedical Industry Chain Alliance(YBDIA)and Huoshi Creation.Jin Xia stated that the index consists of three primary indicators:integration foundation,integration path,and integration effect,eight secondary indicators,20 tertiary indicators,and 28 fourth level indicators.It quantitatively evaluates the integrated development of the biopharmaceutical industry in 41 cities in the three provinces and one city of the Yangtze River Delta.The results show that in the past three years,the integration index of the biopharmaceutical industry in the Yangtze River Delta has shown a continuous growth trend.The integration index of the biopharmaceutical industry in the Yangtze River Delta in 2023 is 163.3,indicating a steady improvement in the foundation of integration,stable enhancement of integration factors,and stable and improved integration results.
Regarding the future,”we hope that the integration of the Yangtze River Delta can be further integrated in policies,systems,infrastructure construction,and other aspects,so that the Yangtze River Delta region can represent China in participating in global top industry competition.”Jin Xia said that she hopes that the biopharmaceutical industry can further unify in ethical mutual recognition,data element circulation,and other aspects in the future,promoting the development of”Yangtze River Delta integration”to accelerate.